Professor, Medicine, UCSD School of Medicine
Internal Medicine
Dr. Joseph L. Witztum, MD
|
|
Give Review
Doctor Joseph L. Witztum, MD practices Internal Medicine. He studied medicine at Mount Sinai School of Medicine. He received awards:"Elected Member". Joseph Witztum is a published doctor and has 102 publications published. The lastest was: 'Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: Phase 2 randomized trial results.' Joseph L. Witztum, MD accepts all Medicare patients.
Publications
- Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice.
- Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society ...
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
- Biomarkers of NAFLD progression: a Lipidomics approach to an epidemic.
- Re-evaluation of the anticoagulant properties of high-density lipoprotein-brief report.
- Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies.
- ABCG1 Is Required for Pulmonary B-1 B Cell and Natural Antibody Homeostasis.
- Targeting APOC3 in the familial chylomicronemia syndrome.
- Reducing Macrophage Proteoglycan Sulfation Increases Atherosclerosis and Obesity through Enhanced Type I Interferon Signaling.
- Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprot...
- Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions.
- Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a): Prospective 15-Year Outcomes in the Bruneck Study.
- Interleukin-3/Granulocyte Macrophage Colony-Stimulating Factor Receptor Promotes Stem Cell Expansion, Monocytosis, and Atheroma Macrophage Burden in Mice With Hematopo...
- Release and Capture of Bioactive Oxidized PhosphoLipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans.
- New Therapeutic Targets for Calcific Aortic Valve Stenosis: The Lipoprotein(a)-Lipoprotein-Associated Phospholipase A2-Oxidized PhosphoLipid Axis.
- Innate Response Activator B Cells Aggravate Atherosclerosis by Stimulating TH1 Adaptive Immunity.
- Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized PhosphoLipids and Lipoprotein (a).
- Development and Application of a Non-Radioactive Binding Assay of Oxidized LDL to Macrophage Scavenger Receptors.
- Intermittent Hypoxia and Hypercapnia induce Pulmonary Artery Atherosclerosis and Ventricular Dysfunction in Low Density Lipoprotein Receptor Deficient Mice.
- The Influence of Innate and Adaptive Immune Responses on Atherosclerosis.
- Determinants of Binding of Oxidized PhosphoLipids on Apolipoprotein (a) and Lipoprotein (a).
- MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma.
- Oxidation-specific biomarkers and risk of peripheral artery disease.
- Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis.
- Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke.
- Adaptive immunity in atherogenesis: new insights and therapeutic approaches.
- Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.
- Oxidized phosphoLipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.
- The Bcl6-SMRT/NCoR Cistrome Represses Inflammation to Attenuate Atherosclerosis.
- In vivo visualization and attenuation of oxidized Lipid accumulation in hypercholesterolemic zebrafish.
- Is atherosclerosis an allergic disease?
- B-Cell Aortic Homing and Atheroprotection Depend on Id3.
- Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.
- Relationship of IgG and IgM autoantibodies and immune complexes to oxidized low density lipoprotein with markers of oxidation and inflammation and cardiovascular event...
- High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised Lipids.
- Oxidative damage in multiple sclerosis lesions.
- Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation.
- Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice.
- Research resource: Comparative nuclear receptor atlas: basal and activated peritoneal B-1 and B-2 cells.
- Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity.
- 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.
- Oxidized low-density lipoprotein and atherosclerosis.
- Atherogenic Lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress.
- Changes in lipoprotein(a), oxidized phosphoLipids, and LDL subclasses with a low-fat high-carbohydrate diet.
- Oxidized cholesteryl esters and phosphoLipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation.
- Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.
- Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice.
- Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: p...
- ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis.
- Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway.
- When monocytes come (too) close to our hearts.
- Deletion of the basement membrane heparan sulfate proteoglycan type XVIII collagen causes hypertriglyceridemia in mice and humans.
- Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium.
- Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.
- Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice.
- Critical role of IL-17RA in immunopathology of influenza infection.
- Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake.
- Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels.
- Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis.
- Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.
- Vascular Lipid accumulation, lipoprotein oxidation, and macrophage Lipid uptake in hypercholesterolemic zebrafish.
- Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage.
- Relationship of oxidized phosphoLipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results fr...
- The role of innate immunity in atherogenesis.
- Fifty years of research on Lipids.
- Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent acti...
- Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Br...
- In memoriam: Roger A. Davis (1945-2008).
- A novel function of lipoprotein [a] as a preferential carrier of oxidized phosphoLipids in human plasma.
- Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phosphoLipids on human apolipoprotein B-100 particles in li...
- Evidence mandating earlier and more aggressive treatment of hypercholesterolemia.
- Host-derived oxidized phosphoLipids and HDL regulate innate immunity in human leprosy.
- Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVE...
- Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes.
- The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
- Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein.
- Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology...
- Promise of immune modulation to inhibit atherogenesis.
- Oxidized phosphoLipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
- Inhibition of the renin-angiotensin system abolishes the proatherogenic effect of uremia in apolipoprotein E-deficient mice.
- ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and Osteopenia.
- A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome.
- Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
- Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.
- Increased plasma oxidized phosphoLipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phosphoLipids from atherosclerotic lesions after dietary Lipid...
- Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule.
- A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions.
- Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
- Oxidized phosphoLipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective result...
- Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
- Minimally oxidized LDL offsets the apoptotic effects of extensively oxidized LDL and free cholesterol in macrophages.
- Rosuvastatin: an independent analysis of risks and benefits.
- Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary interv...
- You are right too!
- Oxidized phosphoLipids, Lp(a) lipoprotein, and coronary artery disease.
- The role of natural antibodies in atherogenesis.
- Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis...
- Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages.
- A comprehensive classification system for Lipids.
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: Phase 2 randomized trial results.
- Population and Assay Thresholds for the Predictive Value of Lipoprotein(a) for Coronary Artery Disease: The EPIC-Norfolk Prospective Population Study.
Schools
Washington Center School of Medicine
Mt Sinai Hospital
Conditions Treated
- HyperLipidemia
- Hypothyroidism
- Lipid Disorders
- Osteopenia
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Elected Member
Education
-
Mount Sinai School of Medicine -
Washington University School of Medicine in St. Louis
Drug Facts
| NPI NUMBER | 1699791491 | |
| NPPES Provider LastName | WITZTUM | |
| NPPES Provider FirstName | JOSEPH | |
| NPPES Provider ZIPCode | 920935004 | |
| NPPES Provider State | CA | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 44.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1699791491 |
| Last Name Of The Provider | WITZTUM |
| First Name Of The Provider | JOSEPH |
| View All |
Similar Doctors
|
Dr. Robert I. Fox, MD |
|
|
Dr. Leila N. Rhodes, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas M. Crowley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David W. Wetherhold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dan E. Dworsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Graves, MD |